Get rid of the third vacancy that receives green light in United States (after Pfizer-BionTech and Modern) and the first to require a single dose, which facilitates notably the logistics of distribution.
Results from Phase III clinical trials that included a total of 45,000 participants demonstrated in probable countries (EEUU, Suramerica and South Africa), the vaccine was released 66% effective in preventing the development of a moderate illness (72% specifically in EUUU), but above all 86% effective in preventing severe illness and 100% effective in preventing death by covid-19.
Women who do not “conform” to a lower percentage of protection in the prevention of synthetic diseases that are increased by Pfizer or Modern vacancies around 95%, María Elena Bottazzi, Honduran microbiologist, code director of the University of the Center Baylor in Houston, the record shows that covid-19 is a nurse who has more than 1100 patients by day, and that approximately 10-15% of the cases progressed to being held severely and have been criticized, which requires hospitalization.
“At this moment the important thing is to be evacuated in order to reduce the chance of suffering a serious illness, criticizing it or the chance of dying. For this the people need to accept the vacancy with any vacancy authorized and available without hope. Although the efficiency varies between vacancies we know that some protection is better than being completely unprotected. For example, the J&J vaccine protects 85% against severe and critical illness and is very similar to the protection by Pfizer and Moderna “, reports Univision Noticias.
Además, some experts like Ashish K. Jha, Dean of the School of Public Health at Brown University, advised that no series just compares to this vaccine with the Modern or the Pfizer pues fue this tried in different places and at a moment different from the pandemic, an important factor is taken into account when he appeared new variants of coronavirus. In Suráfrica, where a pre-emptive variant is circulating, the J&J vaccine has a drug efficiency of 66% and 84%, respectively, to prevent severe disease.
Less secondary effects and indications that prevent contagion
The vaccine demonstration offers consistent protection between the distinct racial groups and editions, although there is a minor impairment in 60 people with pre-existing conditions such as cardiac disease or diabetes.
Tambien to induce lesser secondary effects. The most frequent flurry of pain in the brazier, cabbage pain or song and is resolved in a day or two. No allergic reactions are reported as it has occurred in some cases with Pfizer or Moderna.
The laboratory revised and provided asymptomatic cases with evidence of antichrists 71 days after receiving the injection to 2,650 participants. An analysis of this small group of volunteers determines a 74% efficacy against asymptomatic infection, although in an analysis of the data, the FDA declares that “there is no doubt about this data and no definite conclusions can be drawn at this time”.
It is hoped that the recommendation of the Committee of Experts will authorize the emergence authorization by the FDA. The next step will be a meeting of the Immunization Committee of the Centers for Disease Control and Prevention to discuss who needs to be vaccinated.
But initially did not release available doses, due to manufacturing problems. The pharmaceutical company has agreed to send 20 million of the dose of the vaccine for the March finals and a total of 100 million of the dose for June.
We will explain the attributes of this important vacancy: